Drugs

Mahita LLC dba PushMyCart

FDA issued a warning letter to Mahita LLC dba PushMyCart (Richmond, TX, United States) on Nov 17, 2025, citing 21 CFR 201.128. Subject: Unapproved New Drugs.

From the letter: “Your Mahita products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure…”

Richmond, TX, United StatesIssued Nov 17, 2025Posted Nov 25, 2025No close-out recorded

At a glance

What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.

Violations
4 findings · 2 issue types
Response due
15 working days after receipt of this letter
FDA asks for
4 actions
Named as possible actions
Seizure, injunction
Issued by
Center for Drug Evaluation and Research
Published status
No close-out recorded

AI assisted findings

Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.

01Labeling, claims & marketing · 21 CFR 201.128Your Mahita products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigatio
Your Mahita products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body.
02Labeling, claims & marketingYour Mahita products are especially concerning from a public health perspective. As described below, the labeling of your unapproved “Morbillinum 10M CH,” “Morb
Your Mahita products are especially concerning from a public health perspective. As described below, the labeling of your unapproved “Morbillinum 10M CH,” “Morbillinum 200 CH,” “Cornus Circinata 12 CH,” “Ocimum Canum 200 CH,” “Tarentula Hispana 30 CH,” “Nux Mosch 10M,” “Kerala Ayurveda Parkinsons Choornam,” “Maharishi Ayurveda Erand Pak,” “Dibonil Drop,” and “Wheezal WL16 Drop” drug products includes claims to cure, mitigate, treat, or prevent serious and/or life-threatening conditions such as measles, cancer, diabetes, Parkinson’s and hepatitis, and may cause consumers to forgo, delay, or discontinue medical treatments that have been found safe and effective for such conditions through the FDA review process.
03Labeling, claims & marketingIn addition, your unapproved “REPL Dr. Advice No.45 Glaucoma Drop,” drug product is concerning because ophthalmic drug products, which are intended for administ
In addition, your unapproved “REPL Dr. Advice No.45 Glaucoma Drop,” drug product is concerning because ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.
04Registration, listing & premarketYour Mahita products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GR
Your Mahita products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

What FDA requested

  • Notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations.
  • Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation.
  • If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.
  • If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.

FDA Warning Letter

67 paragraphs · 13 sections

Text as published on FDA.gov, retrieved Sep 8, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)

1WARNING LETTER

6 paragraphs

November 17, 2025

RE: 716286

Mahesh Chada:

This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https://pushmycart.com/ in September 2025. The FDA has observed that your website offers, “Morbillinum 10M CH,” “Morbillinum 200 CH,” “Cornus Circinata 12 CH,” “Ocimum Canum 200 CH,” “Tarentula Hispana 30 CH,” “Nux Mosch 10M,” “Kerala Ayurveda Parkinsons Choornam,” “Maharishi Ayurveda Erand Pak,” “REPL Dr. Advice No.45 Glaucoma Drop,” “Dibonil Drop,” and “Wheezal WL16 Drop” (hereinafter Mahita products) for sale in the United States. We have also reviewed your Facebook account at https://www.facebook.com/pushmycartglobal where you direct consumers to your https://pushmycart.com/ website to purchase your products. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

Your Mahita products are especially concerning from a public health perspective. As described below, the labeling of your unapproved “Morbillinum 10M CH,” “Morbillinum 200 CH,” “Cornus Circinata 12 CH,” “Ocimum Canum 200 CH,” “Tarentula Hispana 30 CH,” “Nux Mosch 10M,” “Kerala Ayurveda Parkinsons Choornam,” “Maharishi Ayurveda Erand Pak,” “Dibonil Drop,” and “Wheezal WL16 Drop” drug products includes claims to cure, mitigate, treat, or prevent serious and/or life-threatening conditions such as measles, cancer, diabetes, Parkinson’s and hepatitis, and may cause consumers to forgo, delay, or discontinue medical treatments that have been found safe and effective for such conditions through the FDA review process. In addition, your unapproved “REPL Dr. Advice No.45 Glaucoma Drop,” drug product is concerning because ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.

Based on a review of your website, your Mahita products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. Examples from your product labeling, including on your website and Facebook account, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:

2Morbillinum 10M CH

3 paragraphs

On the webpage https://pushmycart.com/products/dr-willmar-schwabe-india-morbillinum-dilution-10m-ch?_pos=1&_sid=ba209cbc7&_ss=r:

“[P]rimarily used to treat skin infections.”

“Benefits And Uses . . .o Known for its use in preventing and curing measleso Its [sic] also used to cure skin infections disorderso This dilution is also used in the treatment of ear and eye infections, cough”

3Morbillinum 200 CH

4 paragraphs

On the webpage https://pushmycart.com/products/sbl-morbillinum-dilution-200-ch?_pos=1&_sid=84daa9380&_ss=r:

“SBL Morbillinum Dilution is a measles nosode also known under the name of rubeola or red measles. It us used to give relief from skin itching, skin irritation and eruptions with cough.”

“Key Benefits:o Catarrh, cough, coryza are all treated by taking the right dosage of morbillinumo Chiefly used as a prophylactic against infection, and to clear up after-effects of an attacko Cures the poison of measles that has a great affinity for the mucous passages, the eyes, the ears and the respiratory mucous membranes”On a September 8, 2022 video post on your Facebook account at https://www.facebook.com/pushmycartglobal:

“Suffering from Measles? don't worry pushmycart offers you most effective homeopathic remedies to get rid of MeaslesOrder Measles homeopathic medicines from pushmycart(link to order) . . .SBL Morbillinum Dilution 200 CHhttps://pushmycart.com/.../sbl-morbillinum-dilution-200-ch . . .#measles #measlesoutbreak #measlesawareness #measlesattack #measlesbegone”

4Cornus Circinata 12 CH

4 paragraphs

On the webpage https://pushmycart.com/products/sbl-cornus-circinata-dilution-12-ch?_pos=1&_sid=c1bb0df51&_ss=r:

“SBL Cornus Circinata Dilution is helpful in treatment of diseases like malaria, jaundice and hepatitis. It helps in relieving pain in the abdomen and pit of the stomach. Chronic liver related ailments and pain in genitals and buttocks can also be cured by its use. It also helps in reducing soreness at base of mouth and gum.” • “Key Benefits:o Used for the treatment of malaria, jaundice, hepatitis and other serious renal ailmentso Reduces morning weaknesso Relieves stomach and abdomen paino Relieves genital and buttock eruptionso Relieves mouth and gum sorenesso Relieves mouth, gum and tongue ulcerso Reduces burning sensation in stomach, throat, and moutho Useful for treating bilious diarrhea, dark stools, and anus burningo Helps in curing vesicular eczema on a newborn's face”

On a November 3, 2022 post on your Facebook account at https://www.facebook.com/pushmycartglobal:

“Suffering from Hepatitis C? don't worry pushmycart offers you most effective homeopathic remedies to get rid of Hepatitis C problemOrder Hepatitis C homeopathic medicines from pushmycart(link to order) . . .SBL Cornus Circinata Dilution 12 CHhttps://pushmycart.com/.../sbl-cornus-circinata-dilution . . .#hepatitisc #hepatitisccure #hepatitiscure #hepatitiscdrugs #hepatitisccommunity #hepatitiscawarness #hepatitiscmedicine #hepatitis #hepatitisawareness”

5Ocimum Canum 200 CH

3 paragraphs

On the webpage https://pushmycart.com/products/dr-willmar-schwabe-india-ocimum-canum-dilution-200-ch?_pos=1&_sid=35bcf0fdd&_ss=r:

“Dr Willmar Schwabe India Ocimum Canum Dilution 200 CH is useful remedy for the treatment of ailments like asthma, ophthalmia neonatorum, worm related complaints, cold, typhoid, and tonsillitis. It is helpful for treating a remittent fever”

“Benefits And Uses Of Dr Willmar Schwabe India Ocimum Canum Dilution 200 CHo Helps in reducing intermittent fevero Reduces fever with bone paino Cough, flu, tonsillitis and influenza”

6Tarentula Hispana 30 CH

3 paragraphs

On the webpage https://pushmycart.com/products/dr-willmar-schwabe-india-tarentula-hispana-dilution-30-ch?_pos=1&_sid=baf91c4f4&_ss=r:

“Dr Willmar Schwabe India Tarentula Hispana Dilution 30 CH is a homeopathic solution that can be used for a variety of ailments including headache, restlessness, ADHD, autism and behavioral problems in children. It helps in preventing against many types of mood variations”

“Benefits And Uses Of Dr Willmar Schwabe India Tarentula Hispana Dilution 30 CHo It helps in treating hyperactivity and restless leg syndromeo Migraineso Helps in ADD and ADHD”

7Nux Mosch Dilution 10M

3 paragraphs

On the webpage https://pushmycart.com/products/dr-reckeweg-germany-nux-mosch-dilution-10m-ch?_pos=1&_sid=5a9dc526b&_ss=r:

“Dr. Reckeweg Germany Nux Mosch Dilution 10M CH is primarily used for the treatment of allergy, symptoms related to Alzheimer's Disease, colic, confusion, weak memory, sore throat, constipation and vertigo.”

“Benefits And Uses Of Dr. Reckeweg Germany Nux Mosch Dilution 10M CHo It is also used for the treatment of symptoms related to Alzheimers [sic] Diseaseo Improves memory and concentrationo It is helpful in the treatment of dry mouth and sore throat”

8Kerala Ayurveda Parkinsons Choornam

3 paragraphs

On the webpage https://pushmycart.com/products/kerala-ayurveda-parkinsons-choornam?_pos=1&_sid=e571a60f2&_ss=r:

“Kerala Ayurveda Parkinsons Choornam 50 g is an herbal powder formulation used in Ayurveda, the traditional medicine system of India, to manage Parkinson's disease. Parkinson's Choornam contains several herbs believed to benefit the nervous system and brain.”

“Benefits and Uses of Kerala Ayurveda Parkinsons Choornam[ ]o Improving motor symptomso Boosting cognitive functiono Reducing inflammationo Improving sleep”

9Maharishi Ayurveda Erand Pak

3 paragraphs

On the webpage https://pushmycart.com/products/maharishi-ayurveda-erand-pak-for-management-of-rheumatoid-arthritis-100g?_pos=1&_sid=84d1c5f54&_ss=r:

“For Management Of Rheumatoid Arthritis . . . medicine used for abdominal colic pain, bloating, rheumatoid arthritis etc.”

“Benefits And Uses Of Erand Pak - For Management Of Rheumatoid Arthritis (100gms)o Abdominal paino Edemao Inflammationo Asciteso Urinary tract disorders”

10REPL Dr. Advice No.45 Glaucoma Drop

4 paragraphs

On the webpage https://pushmycart.com/products/repl-dr-advice-no-45-glaucoma-drop?_pos=1&_sid=acd3a4612&_ss=r:

From the product packaging:o In the name of the product – “Glaucoma”

“REPL Dr. Advice No.45 Glaucoma Drop is an herbal formulation designed to help manage glaucoma and support eye health. . . . This product is typically used as an adjunctive therapy to manage eye pressure and promote overall eye wellness.”

“Benefits and useso Helps Manage Intraocular Pressure (IOP)o Supports Overall Eye Healtho Natural Antioxidant Supporto May Reduce Eye Irritationo Enhances Blood Circulation in the Eyeso Helps Slow the Progression of Glaucoma”

11Dibonil Drop

5 paragraphs

On the webpage https://pushmycart.com/products/sbl-dibonil-drop?_pos=1&_sid=89b4359f3&_ss=r:

“[D]eveloped to manage increased blood sugar. It takes care of associated symptoms and delays complications of high blood sugar, thus improving the lives of people with diabetes and enabling them to get back into their everyday lives. SBL Dibonil Drop checks the commonly associated problems of diabetes and has no side effects.”

“Benefits and Uses of SBL Dibonil Dropso Effective in frequent urination.o It helps to decrease excessive thirst.o Relieves and checks cramps and muscular pain.o It builds up tissues and overcomes mental and physical fatigue.”

On an August 30, 2022 post on your Facebook account at https://www.facebook.com/pushmycartglobal:

“Suffering from Diabetes? don't worry pushmycart offers you most effective homeopathic remedies to get rid of DiabetesOrder Diabetes homeopathic medicines from pushmycart(link to order) . . .SBL Dibonil Drophttps://pushmycart.com/products/sbl-dibonil-drop#diabetes #diabete #bloodsugarlevels #bloodsugarlevel #bloodsugarlevelcontrol #bloodsugarlevelsbalanced #bloodsugarcontrol”

12Wheezal WL 16 Drops

6 paragraphs

On the webpage https://pushmycart.com/products/wheezal-wl16-hypertension-drop?_pos=2&_sid=44e55e62d&_ss=r:

From the product packaging:o “Hypertension Dropso Helps Regulate Blood Pressure”

“Wheezal WL16 Hypertension Drop . . . active constituent reserpine, which is well-known for its antipsychotic and antihypertensive action. It is used for calming the central nervous system and helps reduce anxiety.”

“Benefits and Uses of Wheezal WL16 Hypertension Dropo Useful to manage high blood pressureo Reduces symptoms such as irregular beats, increased emotional excitability, irritative condition of CNS, mild depression, irritability, and restlessnesso It is also used in cases of hypertension without marked atheromatous changes in the vesselso It decreases the frequency of loose stools, checks bleeding and alleviates pain”

Your Mahita products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

We recognize that your “Morbillinum 10M CH,” “Morbillinum 200 CH,” “Cornus Circinata 12 CH,” “Ocimum Canum 200 CH,” “Tarentula Hispana 30 CH,” “Nux Mosch 10M,” “REPL Dr. Advice No.45 Glaucoma Drop,” “Dibonil Drop,” and “Wheezal WL16 Drop” drug products are labeled as homeopathic drugs. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.

13Conclusion

4 paragraphs

The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.

This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.

Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.

Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “716286” in the subject line of the email.

Sincerely,/S/

Brad Pace, J.D.Associate DirectorOffice of Unapproved and Labeling ComplianceSigned on behalf of:

Tina Smith, M.S.Captain, U.S. Public Health ServiceDirectorOffice of Unapproved Drugs and Labeling ComplianceOffice of ComplianceCenter for Drug Evaluation and ResearchFood and Drug Administration

Citations and trends

Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 3, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.

Regulations

Issue types

Record details

Issuing center
Center for Drug Evaluation and Research
Issuing office
Center for Drug Evaluation and Research
Location
Richmond, TX, United States
Letter posted date
Nov 25, 2025
Letter issue date
Nov 17, 2025
Addressed to
CEO
Inspection dates
Not recorded
Response window
15 working days after receipt of this letter
Read the source clause
Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations.
Record length
1,975 words · 0 recorded redactions
Published status
No published close-out
Original letter
View on FDA.gov (opens in a new tab)
Dataset last checked
Nov 11, 2026 · How this is built

A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.

See the pattern across 1,707 lettersFind letters like this →
Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

Find letters like this →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.